How to Fight Insurance Denials for Glaucoma Treatment: A Patient Guide

Glaucoma treatment denials are frustratingly common because insurers view glaucoma care through a rigid "step-therapy" lens: they want you to fail generic latanoprost, then add generic timolol, then try combinations, before they'll consider newer medications like Vyzulta, Rhopressa, or Rocklatan—or procedures like selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS). The stakes are high: untreated or under-treated glaucoma causes irreversible vision loss. This guide explains why insurers deny glaucoma treatments, which clinical evidence they actually respect, and how to construct appeals that work.

Why Insurers Deny Glaucoma Treatment

1. "Not medically necessary—try generic drops first"

This is the most common denial template. Your ophthalmologist prescribes Vyzulta (latanoprostene bunod), Rhopressa (netarsudil), or Rocklatan (netarsudil/latanoprost fixed-dose combo), and the insurer responds that you must first fail latanoprost generic, then travoprost or bimatoprost, then add a generic beta-blocker (timolol) or carbonic anhydrase inhibitor (dorzolamide), before accessing "non-preferred" agents. Similarly, insurers will deny SLT or MIGS by saying you haven't exhausted medical therapy—even when the evidence shows SLT works as first-line treatment.

2. "Experimental / investigational procedure"

MIGS devices—iStent inject W, Hydrus Microstent, Xen Gel Stent, OMNI, Kahook Dual Blade (KDB)—earn this label frequently. Insurers claim there's insufficient long-term data, even though these devices have FDA approval and appear in American Academy of Ophthalmology (AAO) Preferred Practice Patterns. Intracameral implants (Durysta, iDose TR) also get flagged as "experimental" despite FDA approval and peer-reviewed trials.

3. "Must be performed concurrent with cataract surgery"

Many MIGS devices received FDA approval with a label specifying "in conjunction with cataract surgery." Insurers use this to deny standalone MIGS (surgery without phacoemulsification) even when your lens is clear, you're pseudophakic, or your glaucoma is severe and won't wait for a cataract to ripen. The clinical reality: surgeons routinely perform MIGS standalone when medically appropriate, and some devices (Xen, OMNI, KDB) have standalone indications.

4. "Preservative-free formulation not covered—use the generic"

You have severe ocular surface disease from years of benzalkonium chloride (BAK) exposure in standard drops, your ophthalmologist prescribes Xelpros (BAK-free latanoprost), Travatan Z (BAK-free travoprost), Zioptan (preservative-free tafluprost unit-dose), or Cosopt PF, and the insurer denies it, telling you to use generic latanoprost with BAK. This ignores published data on BAK toxicity and its impact on adherence and surgical outcomes.

5. "Trabeculectomy or tube shunt not authorized—try more drops or repeat SLT"

For advanced, refractory glaucoma—when you've exhausted drops, had SLT, perhaps tried MIGS—insurers still balk at covering trabeculectomy or tube-shunt surgery (Baerveldt, Ahmed). They'll ask for yet another medication trial or repeat laser, delaying filtration surgery even when your visual field is collapsing and your retinal nerve fiber layer (RNFL) is thinning on OCT.

The Citations Insurers Respect

When you appeal, reference these specific guidelines, trials, and policy statements by name and year. Insurers are more likely to overturn denials when you cite the same evidence their medical directors rely on:

Clinical Practice Guidelines

• American Academy of Ophthalmology Preferred Practice Pattern: Primary Open-Angle Glaucoma (2020, updated regularly)

The AAO PPP is the authoritative U.S. guideline. It endorses SLT as first-line therapy equivalent to drops, describes MIGS devices, and emphasizes individualized treatment escalation. When the insurer claims something is "experimental," cite the PPP's inclusion of that device or procedure.

• European Glaucoma Society Guidelines (5th Edition, 2020)

International standard covering medical, laser, and surgical management. Useful when appealing denials of newer drugs or MIGS; EGS discusses Rho-kinase inhibitors, NO-donating prostaglandins, and ab interno procedures.

Landmark Trials for SLT

• LiGHT Trial (Lancet 2019)

The Laser in Glaucoma and Ocular Hypertension Trial randomized 718 patients with newly diagnosed open-angle glaucoma or ocular hypertension to SLT-first vs. drops-first. At 36 months, SLT-first patients had better quality of life, fewer drops, lower cost, and equivalent IOP control. This trial dismantles the "SLT is only for failures of medical therapy" argument.

MIGS Pivotal Trials

• iStent inject: Samuelson et al., Ophthalmology 2011 (original iStent); FDA pivotal for iStent inject 2018 / inject W 2020

Prospective randomized controlled trials showing IOP reduction and medication reduction when iStent trabecular micro-bypass is implanted with cataract surgery. Appeal letters should cite both FDA approval dates and peer-reviewed outcomes data.

• Hydrus Microstent (HORIZON trial): Samuelson et al., Ophthalmology 2019

Multicenter RCT: Hydrus + cataract surgery vs. cataract alone. At 24 months, 77.3% of Hydrus patients were medication-free vs. 57.8% controls; mean IOP reduction was greater. FDA approved August 2018 based on this trial.

• Xen Gel Stent: Grover et al., J Glaucoma 2014; Schlenker et al., Ophthalmology 2017

Real-world case series and comparative studies. Xen received FDA approval November 2016 for ab interno subconjunctival drainage. While some insurers call it experimental, cite FDA clearance and published 1- and 2-year outcomes.

• OMNI: Surgical System FDA clearance 2018; Dorairaj et al., Clinical Ophthalmology 2020

Canaloplasty + trabeculotomy in one pass. FDA cleared for standalone or combined use. Published series show IOP reduction and medication burden decrease; cite these when insurers deny standalone OMNI.

• Kahook Dual Blade (KDB): FDA clearance 2015; Dorairaj et al., Ophthalmology Glaucoma 2018 / 2020

Ab interno trabeculotomy technique. Multiple prospective case series and registry data. Not experimental—cite FDA date and peer-reviewed outcomes.

Intracameral Implants

• Durysta (bimatoprost SR): FDA approval March 2020; ARTEMIS trials (Medeiros et al., Ophthalmology 2020)

Phase 3 RCTs showed sustained IOP reduction over 12–15 weeks from a single intracameral bimatoprost implant. When insurers deny as "experimental," cite FDA approval and ARTEMIS-1 and -2 by name.

• iDose TR (travoprost SR): FDA approval December 2023; Phase 3 trials (Brandt et al., Ophthalmology 2023)

Sustained-release travoprost implant, refillable, with 12+ month durability. Very recent approval, so insurers often lack policy; cite FDA approval letter and published Phase 3 data.

Medications: Vyzulta, Rhopressa, Rocklatan

• Vyzulta (latanoprostene bunod 0.024%): FDA approval November 2017; APOLLO and LUNAR trials (Weinreb et al., Am J Ophthalmol 2016; Ophthalmology 2018)

Nitric oxide–donating PGA. Pivotal trials showed greater IOP reduction than latanoprost 0.005%. When denied as "not superior to generic," cite APOLLO/LUNAR head-to-head data.

• Rhopressa (netarsudil 0.02%): FDA approval December 2017; ROCKET trials (Serle et al., Am J Ophthalmol 2018; Ophthalmology 2018)

Rho-kinase inhibitor, novel mechanism (increases trabecular outflow, lowers episcleral venous pressure). When denied, cite ROCKET-1, -2, -4 showing non-inferiority to timolol and additive effect to PGA.

• Rocklatan (netarsudil 0.02%/latanoprost 0.005%): FDA approval March 2019; MERCURY trials (Asrani et al., Ophthalmology 2019)

Fixed-dose combo of Rho-kinase inhibitor + PGA. MERCURY-1 and -2 showed greater IOP reduction than either component alone. Cite these when insurer says "just use latanoprost generic plus a second drop."

Preservative-Free Formulations and BAK Toxicity

• Baudouin et al., Prog Retin Eye Res 2010; Pisella et al., Br J Ophthalmol 2002

Landmark reviews documenting BAK's toxic effects on cornea, conjunctiva, tear film, and eventual impact on trabeculectomy bleb survival. When appealing for Xelpros, Travatan Z, Zioptan, or Cosopt PF, cite these to establish medical necessity of preservative-free therapy.

• AAO PPP (2020) Section on Medication Adherence and Tolerability

PPP acknowledges BAK intolerance as a reason to switch to preservative-free or alternative agents.

Trabeculectomy and Tube Shunts

• Tube Versus Trabeculectomy (TVT) Study: Gedde et al., Ophthalmology 2012; Am J Ophthalmol 2018 (5-year)

Randomized comparison of Baerveldt tube vs. trabeculectomy with MMC. Both effective; trabeculectomy had slightly higher failure rate but lower reoperation rate. Cite TVT when insurer questions medical necessity of either procedure.

• Primary Tube Versus Trabeculectomy (PTVT) Study: Gedde et al., Ophthalmology 2018

In patients without prior incisional surgery, trabeculectomy and tube were similarly effective at 3 years. Use this to argue for either option depending on surgeon recommendation.

• Ahmed Baerveldt Comparison (ABC) Study: Budenz et al., Ophthalmology 2015; 2016 (3- and 5-year)

Head-to-head valved (Ahmed) vs. non-valved (Baerveldt) implants. Helps justify choice of device when insurer tries to dictate which tube to use.

How to Argue Against Each Denial Reason

Fighting "Not medically necessary—try generic drops first"

For newer medications (Vyzulta, Rhopressa, Rocklatan, intracameral implants):

1. Document inadequate IOP control or intolerance on generic regimen.

Your appeal letter must list every drop tried: latanoprost 0.005% for X months → IOP remained Y mmHg above target or caused hyperemia/keratitis; timolol → bradycardia or insufficient additional IOP reduction; brimonidine → allergic conjunctivitis; dorzolamide → stinging/non-adherence. Include dates, dosages, IOP measurements, and side effects for each.

2. Cite target IOP and gap.

"Patient's optic nerve and visual field staging place target IOP at ≤14 mmHg per AAO PPP risk stratification. On maximal tolerated medical therapy (latanoprost + dorzolamide-timolol), IOP remains 18–20 mmHg OD. This 4–6 mmHg gap represents ongoing risk of progression."

3. Reference head-to-head trial data.

For Vyzulta: "APOLLO trial (Weinreb, Am J Ophthalmol 2016) demonstrated latanoprostene bunod reduced IOP 1.23 mmHg more than latanoprost at month 3 (p<0.001). Patient requires this additional margin." For Rocklatan: "MERCURY-1 (Asrani, Ophthalmology 2019) showed netarsudil/latanoprost FDC lowered IOP 1–2 mmHg beyond latanoprost monotherapy."

4. Emphasize adherence.

If you're on three separate bottles bid/tid, document missed doses and request Rocklatan as a single QD bottle to improve adherence—cite AAO PPP's discussion of adherence barriers.

5. For intracameral implants (Durysta, iDose TR): Note FDA approval, cite ARTEMIS or Phase 3 trials, and document adherence failure (tremor, arthritis, cognitive impairment, homelessness) or documented non-adherence log showing missed doses.

For SLT denied as "not first-line":

1. Cite the LiGHT trial by name.

"The LiGHT trial (Gazzard, Lancet 2019) demonstrated SLT-first strategy was clinally and cost-effective compared to drops-first in treatment-naïve open-angle glaucoma. At 36 months, SLT patients had better QoL and fewer medications."

2. Cite AAO PPP 2020.

"AAO Preferred Practice Pattern (2020) lists SLT as an appropriate initial therapy, equivalent in efficacy to prostaglandin analogs, for open-angle glaucoma and ocular hypertension."

3. Highlight patient-specific factors favoring SLT.

Adherence concerns (missed drops), side effects from drops, high pill burden, cost of multi-drug regimen, patient preference for fewer daily medications.

4. Cost argument.

One SLT session (~$500–1,000) vs. years of brand drops at $200–400/month. Include a cost comparison table if possible.

Fighting "Experimental / investigational" for MIGS

1. Cite FDA approval date and indication.

Example: "Hydrus Microstent received FDA approval August 7, 2018 (P170043) for implantation in conjunction with cataract surgery. This is not experimental; it is an approved device."

2. Reference AAO PPP inclusion.

"AAO Primary Open-Angle Glaucoma PPP (2020) discusses trabecular micro-bypass stents (iStent family) and Schlemm's canal scaffolds (Hydrus) as established MIGS procedures."

3. Cite pivotal trial.

For Hydrus: "HORIZON trial (Samuelson, Ophthalmology 2019, PMID 30098374) randomized 556 eyes; Hydrus + phaco showed statistically significant IOP and medication reduction vs. phaco alone at 24 months." For iStent inject: "FDA pivotal trial (Samuelson, Ophthalmology 2011) and subsequent inject studies show safety and efficacy."

4. Address long-term data concern.

If insurer wants "5-year data," point out that FDA approval is granted on 2-year pivotal trials and post-market surveillance continues; waiting for 5 years would deny patients timely care. Cite any available real-world case series with longer follow-up.

5. For Xen, OMNI, KDB standalone: Emphasize that FDA clearance includes standalone use (check device label) and cite published case series. Example: "OMNI received FDA 510(k) K180836 in 2018 for canaloplasty and trabeculotomy, both standalone and combined. Dorairaj et al. (Clin Ophthalmol 2020, PMID 33177781) published 6-month outcomes of standalone OMNI showing mean IOP reduction of 9.2 mmHg."

Fighting "Must be performed concurrent with cataract"

1. Check the device's actual FDA indication.

iStent inject W and Hydrus have cataract-concurrent labels; however, clinical practice and some devices (Xen, OMNI, KDB) explicitly allow standalone use. If the label says "with cataract," acknowledge it but argue medical necessity for off-label standalone use under the following rationale:

2. Severe, progressive glaucoma that cannot wait.

"Patient has severe POAG (MD –12 dB) with documented progression on OCT GPA. Waiting for a cataract to become visually significant (currently 2+ NS, BCVA 20/25) would risk irreversible field loss. AAO PPP supports escalating surgical intervention when medical and laser therapy are insufficient, regardless of lens status."

3. Pseudophakic eye.

"Patient is already pseudophakic OD from cataract surgery in 2023. The FDA label restriction is moot; there is no cataract to combine with. Standalone MIGS is the only option."

4. Cite real-world standalone outcomes.

For iStent: "Published series (e.g., Katz et al., J Glaucoma 2015) report standalone iStent outcomes. While off-label, this is a recognized practice when cataract surgery is not indicated."

5. Request peer-to-peer review.

Ask your ophthalmologist to request a peer-to-peer call with the insurer's medical director to explain the clinical reasoning for standalone MIGS.

Fighting preservative-free denials

1. Document ocular surface disease.

Provide OSDI score, Schirmer test results, tear breakup time, corneal staining grade (Oxford scheme), meibomian gland dysfunction grade. "OSDI score 42 (severe symptoms), Schirmer 3 mm OU (severe dry eye), SPK grade 3 OU."

2. Cite BAK toxicity literature.

"Benzalkonium chloride, the preservative in generic latanoprost, is toxic to the ocular surface (Baudouin, Prog Retin Eye Res 2010, PMID 20398770). Chronic BAK exposure causes goblet cell loss, conjunctival fibrosis, and can compromise future trabeculectomy success (Broadway, Arch Ophthalmol 1994)."

3. Link BAK to prior adverse events.

"Patient developed keratitis and conjunctival hyperemia on BAK-preserved latanoprost, requiring temporary discontinuation. Switching to BAK-free Xelpros or Travatan Z is medically necessary to maintain IOP control without exacerbating ocular surface disease."

4. Highlight future surgical risk.

"Patient is a candidate for trabeculectomy. Continued BAK exposure increases risk of bleb failure due to conjunctival scarring. Preservative-free therapy now protects future surgical options."

5. Cost-effectiveness of adherence.

"Non-adherence due to intolerable burning/stinging leads to uncontrolled IOP and future costs of surgery or vision loss. Preservative-free drops improve tolerability and adherence."

Fighting trabeculectomy or tube-shunt denials

1. Document refractory disease.

"Patient has exhausted maximal medical therapy (4 drops: latanoprost, dorzolamide-timolol, brimonidine) + SLT OU (360° in 2024, initial response, regressed by 9 months) + prior MIGS (iStent inject W OD 2025, IOP reduced 3 mmHg, now regressing). Current IOP 22 mmHg OD on maximal therapy; target ≤14 mmHg."

2. Show progression.

"Humphrey 24-2 visual field: MD OD –12.4 dB, progressed from –9.1 dB 18 months ago (rate –1.8 dB/year). OCT RNFL OD 58 µm (5th percentile), thinning 6 µm over last year per Guided Progression Analysis. This is rapid, sight-threatening progression."

3. Cite AAO PPP escalation pathway.

"AAO PPP (2020) recommends incisional surgery when medical and laser therapy fail to achieve target IOP or when progression continues despite treatment. Patient meets both criteria."

4. Reference TVT/PTVT/ABC studies.

"Tube Versus Trabeculectomy Study (Gedde, Ophthalmology 2012) validates both trabeculectomy and tube-shunt surgery as effective options for refractory glaucoma. Surgeon recommends trabeculectomy with MMC based on patient anatomy and risk profile."

5. Urgency and standard of care.

"Delay risks permanent vision loss. Filtration surgery is the standard of care at this stage per AAO, EGS, and peer-reviewed literature. Requesting further medication trials or repeat SLT would be futile and medically inappropriate."

What We Do

We help patients and families draft and submit appeals when glaucoma treatments—whether medications, laser, or surgery—are denied. We gather your medical records, IOP logs, visual field printouts, and OCT reports, then write evidence-based letters citing the specific trials, guidelines, and FDA approvals that insurers' medical directors recognize. We coordinate with your ophthalmologist's office to get peer-to-peer reviews scheduled and ensure all documentation is complete. Our goal is to get your denial overturned quickly, so you can start or continue the therapy that protects your vision.

---

Sources

1. American Academy of Ophthalmology. Preferred Practice Pattern: Primary Open-Angle Glaucoma. 2020. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp

2. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 5th Edition. 2020. https://www.eugs.org/eng/guidelines.asp

3. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505-1516. PMID: 30862377.

4. Samuelson TW, Katz LJ, Wells JM, et al. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459-467. PMID: 20828829.

5. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126(1):29-37. PMID: 30098374.

6. Grover DS, Godfrey DG, Smith O, et al. Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results. Ophthalmology. 2014;121(4):855-861. PMID: 24412282.

7. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124(11):1579-1588. PMID: 28647203.

8. Dorairaj S, Tam MD, Balasubramani GK, et al. Twelve-month outcomes of goniotomy performed using the Kahook Dual Blade combined with cataract surgery in eyes with medically treated glaucoma. Clin Ophthalmol. 2018;12:1779-1784. PMID: 30275672.

9. Dorairaj S, Radcliffe NM, Stiles MC. Combined canaloplasty and trabeculotomy with the OMNI system in open-angle glaucoma: interim results from the GEMINI study. Clin Ophthalmol. 2020;14:4613-4620. PMID: 33177781.

10. Medeiros FA, Sheybani A, Weinreb RN. Corneal thickness measurements and visual function abnormalities in ocular hypertensive patients. Am J Ophthalmol. 2003;135(2):131-137. (Note: For Durysta ARTEMIS trials, see:) Medeiros FA, Sheybani A, Weinreb RN, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627-1641. PMID: 32828868.

11. Brandt JD, DuBiner HB, Benza R, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2023;130(5):471-481. (For iDose TR travoprost implant Phase 3 data.) PMID: 36566952.

12. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973. PMID: 26875000.

13. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled Phase 3 study findings. J Glaucoma. 2018;27(Suppl 1):S7-S15. PMID: 29975336.

14. Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127. PMID: 29162486.

15. Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of Phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620-1631. PMID: 32125659.

16. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334. PMID: 20398770.

17. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423. PMID: 11914211.

18. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803.e2. PMID: 22245458.

19. Gedde SJ, Feuer WJ, Shi W, et al. Treatment outcomes in the Primary Tube Versus Trabeculectomy Study after 3 years of follow-up. Ophthalmology. 2018;125(11):1693-1702. PMID: 29986826.

20. Budenz DL, Barton K, Gedde SJ, et al. Five-year treatment outcomes in the Ahmed Baerveldt Comparison Study. Ophthalmology. 2015;122(2):308-316. PMID: 25439606.

21. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-1454. PMID: 7980135.